February 18, 2019
Kyowa Hakko Kirin/Ultragenyx Pharmaceutical’s Crysvita (burosumab) demonstrated positive long-term benefits in children with X-linked hypophosphatemia (XLH), a rare inherited form of rickets, according to the latest data from a global PIII study. The PIII study enrolled 61 patients aged 1-12...read more